GM all, Here you go........CEO email from last night........
Thanks for your interest in the company and your purchase of our products. We believe that we are on the right path in focusing on the pain relief products. You are perceptive, we are in need of money to continue on with our research on the very promising anti-cancer drug. I clearly stated that in our last press release as well as in our last CEO letter to stockholders.
The next phase of our cancer R&D would require us to develop a humanized form of our drug and to conduct further small animal tests on humanized small animals. That will cost about $500K and take about nine months. After that, we would most likely progress to primate animals, and that testing would most likely take about one year and cost about $2.0 million. After those successful tests, we would most likely progress to pre-clinical tests on human volunteers for about 18-24 months, costing about $3.0-$5.0 million. Clinical studies beyond that would necessitate involvement of a Big Pharma partner and could cost many millions of dollars. Clearly, we could not sustain that cost via borrowing against our stock as equity since the earlier parasites had sold us down to sub-penny. So, we had no alternative but to temporarily shelve our project.
Our goal all along was to take the project to a point where Big Pharma would either license the technology and/or partner with us. We knew all along that we would never be able on our own to absorb all of the expense to fully develop our drug and take it to market. In the last year, we have received e-mails and telephone calls from upper management at Pfizer and Novartis seeking additional information on our project, so we know that our progress is being watched. Nonetheless, we were forced to shelve our very promising R&D work pending ingress by either R&D partners or angel investors.
In the interim, we have successfully launched a very promising business venture in the pain management arena. The pain market worldwide is estimated conservatively at $112 billion! We plan to launch an entire array of new products this calendar year with CBD Sprays, Creams, Gel Pens, and Capsules, with the last new product coming out either in late 2017 or early 2018. We are targeting the opioid pain relief market where 28,000 people died just last year in the USA alone from opioid poisoning!
We have had up to five IR/PR firms at one time in the past. They have been ineffective at best. One firm we have now seems to be very effective, and we hope to see a continuation of the recent upswing for the rest of the month and beyond. The good news is that the market has responded favorably to our moves to reinvent the company and our transparency. Major developments are underway that should sustain our progress, and these will be announced to the entire investing community when appropriate.
Again, thanks for your interest in the company. We will not let you down.
William A. Hartman
President/CEO
Premier Biomedical, Inc.
Pain Management Solutions
Office(xxx)xxx-xxxx(Took out his phone number so people don't call him all day long, u can look it up. It's easy to find.
Skype: w.a.hartman
www.premierbiomedical.com
www.painreliefmeds.com
